Clinical trial
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage…
NCT00120328 · Speedel Pharma Ltd., Industry · Terminated
Key facts
| NCT number | NCT00120328 |
|---|---|
| Title | To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy |
| Official title | ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy |
| Lead sponsor | Speedel Pharma Ltd., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | SPP301 |
| Enrollment | 2,364 |
| Start date | Jul 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Jul 15, 2005 |
| Last update posted | Oct 5, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: